Apolipoprotein E Gene and Functional MRI (fMRI)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2012 by Taipei Medical University Shuang Ho Hospital
Sponsor:
Collaborator:
Chang Gung Memorial Hospital
Information provided by (Responsible Party):
Chaur-Jong Hu, Taipei Medical University Shuang Ho Hospital
ClinicalTrials.gov Identifier:
NCT01287819
First received: January 31, 2011
Last updated: October 17, 2012
Last verified: October 2012
  Purpose
  1. Apolipoprotein E gene (ApoE) is the most important genetic factor for Alzheimer disease (AD) and an important genetic factor for outcome of brain injury situations.
  2. Function magnetic resonance imaging (fMRI) is a powerful tool for study of both brain regional functions and brain network.
  3. Study about genetic contribution on fMRI is an emerging concept, which will help on understanding about how the genetics affecting the brain function.

Condition
Dementia

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Polymorphisms of Apolipoprotein E Gene and the Presentation of Resting-state Functional MRI

Resource links provided by NLM:


Further study details as provided by Taipei Medical University Shuang Ho Hospital:

Primary Outcome Measures:
  • amyloid load by amyloid-PET examination [ Time Frame: every 5 years ] [ Designated as safety issue: No ]
    The primary end point of this study is the quantity of amyloid load in brain. The amyloid load will be calculated based on the results of AV45 PET study. The comparison between mTBI and controls will be conducted by ANOVA test. The confounders include vascular risks for AD, such as hypertension, diabetes, and APOE genotypes, education.


Biospecimen Retention:   Samples With DNA

DNA


Estimated Enrollment: 200
Study Start Date: May 2012
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
APOE4 (+) and APE4 (-)
APOE4 (+) 10 people APOE4 (-) 20 people from 200 participants

Detailed Description:

There are about 4-10% people aged and over 65 years suffering from dementia in Taiwan. Dementia caused by diverse diseases, including Alzheimer's disease (AD), fronto-temporal dementia (FTD), dementia with Lewy body (DLB), Parkinson's disease dementia (PDD) and vascular dementia (VaD), is a neurodegenerative disease characterized by memory impairment, cognitive dysfunctions, behavioral disturbances and various kinds of psychiatric manifestations. AD is the most common cause of dementia in the world. Although the real pathophysiology of AD is still obscure, the compelling evidence has shown genetic factor should play an important role in the occurrence of AD. There are three genes, in terms of amyloid precursor protein (APP), presenilin-1 (PS1) and presenilin-2 (PS2), linked in the familial AD. Mutations on these genes would result in familial AD, which account for only less than 5% of AD. The only one well-documented genetic risk factor for sporadic AD is apolipoprotein E, ε4 allele (ApoE4). ApoE gene contains three genetic polymorphisms, ε2, 3, 4 and ApoE4 has been found associated with many brain injury situations, such as poor outcome for traumatic brain injury (TBI), Parkinson disease dementia (PDD). These findings might support ApoE to be important for brain functions but the real mechanisms remain further clarification. Functional magnetic resonance imaging (fMRI) is a powerful tool for study of both brain regional functions and brain network. To our knowledge, only few reports in top journals indicated genetic background is an important contributor for fMRI presentations. This could be a new filed of neuroscience. In this study, we will explore whether ApoE genetic polymorphisms affect the presentation of fMRI and realize some functions of ApoE in the brain. In addition, our data could enhance the new concept about the association between genetics and brain function.

  Eligibility

Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

people aged 45-65 years taking health examination in TMU SHH no cognitive impairment by MMSE and AD8 screening

Criteria

Inclusion Criteria:

  • people aged 45-65 years without cognitive impairment

Exclusion Criteria:

  • unable to take APOE genotyping or undergo functional MRI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01287819

Contacts
Contact: Chaur-Jong Hu, M.D. 886-2-22490088 ext 8112 chaurjongh@tmu.edu.tw

Locations
Taiwan
Chaur-Jong Hu Recruiting
New Taipei City, Taiwan, 235
Contact: Chaur-Jong Hu, M.D.    886-2-22490088 ext 8112    chaurjongh@tmu.edu.tw   
Principal Investigator: Chaur-Jong Hu, M.D.         
Sponsors and Collaborators
Taipei Medical University Shuang Ho Hospital
Chang Gung Memorial Hospital
Investigators
Principal Investigator: Chaur-Jong Hu, M.D. Taipei Medical University Shuang Ho Hospital
  More Information

No publications provided by Taipei Medical University Shuang Ho Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Chaur-Jong Hu, Chief of Neurology department, Taipei Medical University Shuang Ho Hospital
ClinicalTrials.gov Identifier: NCT01287819     History of Changes
Other Study ID Numbers: CRC-12-10-04
Study First Received: January 31, 2011
Last Updated: October 17, 2012
Health Authority: Taiwan: Department of Health

ClinicalTrials.gov processed this record on September 30, 2014